Gilead Sciences, Inc. vs Merck & Company, Inc. — Stock Comparison
Gilead Sciences, Inc. (GILD) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Gilead Sciences, Inc. scores ahead of Merck & Company, Inc. on Q·Score (8.2 vs 7 out of 10), led by Quality (9.6 vs 7.7) and Growth (7.9 vs 6.2). Analyst consensus targets imply greater upside for GILD (+26.8%) than for MRK (+12.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 43% return on equity and 31% profit margins.
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
GILD vs MRK: which stock scores better overall?
Based on Q·Score, Gilead Sciences, Inc. (GILD) scores 8.2/10 versus Merck & Company, Inc. (MRK) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GILD or MRK?
Gilead Sciences, Inc. (GILD) scores higher on Growth (7.9/10 vs 6.2/10). Gilead Sciences, Inc. reports revenue growth (4.4% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GILD or MRK more attractively valued?
Gilead Sciences, Inc. (GILD) scores higher on Valuation (7.7/10 vs 6.7/10). GILD trades at 12.9× P/E versus MRK at 12.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GILD vs MRK?
There are 28 analysts covering GILD with a consensus price target of $157.57, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GILD or MRK?
Gilead Sciences, Inc. (GILD) scores higher on Quality (9.6/10 vs 7.7/10). Net profit margin: GILD at 31.0%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GILD or MRK?
Gilead Sciences, Inc. (GILD) scores higher on Financial Health (7.6/10 vs 7/10). Market beta: GILD at 0.33, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GILD and MRK?
Gilead Sciences, Inc. (GILD) has a market capitalisation of $154.3B, while Merck & Company, Inc. (MRK) has a market cap of $283.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do GILD or MRK pay dividends?
GILD pays a dividend yield of 2.64%, while MRK pays a dividend yield of 2.96%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →